Impact Factor 4.716 | CiteScore 4.71
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.02490

The management of glucocorticoid therapy in liver failure

  • 1Beijing Youan Hospital, Capital Medical University, China

Liver failure is characterized by rapid progression and high mortality. Excessive systemic inflammation is considered as the trigger of liver failure. Glucocorticoids (GCs) can rapidly suppress excessive inflammatory reactions and immune response. Actually, since the 1970s, GCs have been applied in the treatment of liver failure. However, until now, the using of GCs in the treatment of liver failure has been still unclear and controversial. Some brand new researches regarding the molecular mechanisms of GCs may explain the GCs controversial actions in liver failure. More results should be confirmed in a larger randomized clinical trial helping to arrive to better definitions in terms of treatment schedules according to different clinical settings. Meanwhile, the timing and dosing of GCs in the treatment of liver failure should also be explored.

Keywords: Glucocorticoids, Liver Failure, timing, dosing, Inflammation

Received: 16 Apr 2019; Accepted: 04 Oct 2019.

Copyright: © 2019 Xue and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Qinghua Meng, Beijing Youan Hospital, Capital Medical University, Beijing, Beijing Municipality, China,